Other news: ATHN -11.2% ( Greenlight's David Einhorn making cautious comments on ATHN at Ira Sohn, believes it could fall 80%), TWTR -2.7% (TWTR lock up expiration; also reports out discussing video ad launch), LGF -1.6% (Divergent tops $250 mln at the worldwide box office ), MMP -1.5% (announces it is proceeding with its pipeline project to deliver refined petroleum products to Little Rock, Arkansas, supported by commitments from its recent open season), SHPG -1.3% (still checking), DB -0.9% (Moody's Reviews Deutsche Bank (A2 for Deposits) for Possible Downgrade), AMT -0.8% ( announces proposed public offering of mandatory convertible preferred stock ), -0.5% (still checking), AZN -0.5% (receives FDA approval for EPANOVA for the treatment of adults with severe hypertriglyceridemia), BBY -0.4% (disclosed yesterday Chief Commercial Officer Jude C. Buckley resigned to pursue other interests, effective immediately).
M&A related: FST +25.7% (Forest Oil and Sabine Oil & Gas announce definitive merger agreement; cos will combine their businesses under a newly formed holding co, Sabine Oil & Gas Corp), ALU +4.9% (NOK for ALU speculation), YHOO +0.5% (Re Code discusses Alibaba (ALBCF.PK) IPO and that is possible that YHOO could become a takeover target).
Select oil/gas related names showing strength: TLM +1.9% and STO +1% (reports out indicate TLM / STO may sell Texas jv), BP +0.8% (still checking), VLO +0.2% (upgraded to Outperform from Perform at Oppenheimer).
Other news: CODE +4.6% ( Soros Fund Management discloses 5.11% passive stake in 13G filing), HMY +3.3% (still checking), RYAAY+2.5% (still checking), AVGO +2.4% (AVGO to replace LSI in the S&P 500), ARMH +2.4% (strength may be attributed to AMD chip licensing agreement), VOD +1.7% (still checking), CCL +1.5% (still checking), MRK +1.1% (Merck announces sale of Consumer Care business to Bayer for $14.2 bln; enters into collaboration with Bayer to market and develop novel therapies for cardiovascular disease; collaboration includes a $1 bln up-front payment by Merck to Bayer), HSBC +1.1% (boosted by UBS results), TRN +0.9% ( declares a 2-for-1 stock split and a 33% increase in its quarterly dividend to $0.10 per share), TSN +0.8% (modestly rebounding), GTAT +0.3% ( announces larger capacity ASF 165 sapphire furnace), AAPL +0.3% (Smartphone applications shipments fell 4% in China in Q1, according to reports), CTRP +0.3% (Barron's profiles positive views from yesterday's Ira Sohn conference .
Analyst comments: HEAR +3.9% (initiated with a Outperform at Wedbush), SGEN +1% (upgraded to Neutral from Underperform at BofA/Merrill)
Gapping down: ININ -18.4%, AEIS -12.3%, ATHN -12.2%, MED -10.4%, FN -10.2%, SGY -5.3%, MR -4.4%, ECOM -4.4%, HCLP -4.4%, AIG -2.9%, LF -2.9%, BCS -2.8%, YY -2.7%, SMG -2.5%, MTSC -2.3%, VECO -1.9%, PRI -1.8%, BNFT -1.8%, LGF -1.6%, MMP -1.5%, SZYM -1.5%, SHPG -1.3%, DB -0.9%, AMT -0.8%, AZN -0.5%
BN 05/06 10:02 *MERCK TO MAKE AVAILABLE EARLY-STAGE SGC COMPOUNDS AT SAME TERMS
BN 05/06 10:02 *MERCK: PACT ALSO INCLUDES CLINICAL DEVELOPMENT OF VERICIGUAT
BN 05/06 10:01 *MERCK IN CLINICAL DEVELOPMENT PACCT FOR SGC MODULATORS
BN 05/06 10:01 *MERCK SAYS BAYER TO GET MERCK PRESCRIPTION RIGHTS FOR AFRIN
BN 05/06 10:01 *MERCK SAYS BAYER TO GET MERCK PRESCRIPTION RIGHTS FOR CLARITIN
BN 05/06 10:01 *BAYER WILL GET $1B UP-FRONT WITH POTENTIAL FOR ADDED MILESTONES
BN 05/06 10:00 *MERCK TO UPDATE 2014 FINL GUIDANCE WHEN TRANSACTION CLOSES
BN 05/06 10:00 *MERCK SAYS BAYER TO GET MERCK'S EXISTING OTC BUSINESS
BN 05/06 10:00 *MERCK EXPECTS AFTER-TAX PROCEEDS FROM SALE $8B - $9B
BN 05/06 10:00 *MERCK IN PACT W/ BAYER FOR CARDIOVASCULAR THERAPIES
BN 05/06 10:00 *MERCK REPORTS SALE OF CONSUMER CARE TO BAYER AG FOR $14.2 BLN
BFW 05/06 10:00 *MERCK REPORTS SALE OF CONSUMER CARE BUS TO BAYER FOR $14.2B
BN 05/06 10:00 *MERCK PACT INCLUDES A $1B UP-FRONT PAYMENT
BN 05/06 10:00 *MERCK REPORTS SALE OF CONSUMER CARE OPS TO BAYER FOR $14.2B
BN 05/06 10:00 *MERCK REPORTS SALE OF CONSUMER CARE BUSINESS TO BAYER FOR
2014-05-06 10:09:29.472 GMT
By Joanna Ossinger
May 6 (Bloomberg) -- Bayer to buy Merck’s existing OTC
business, including global trademark and prescription rights for
Claritin, Afrin.
* Merck to make upfront $1b payment to Bayer w/ additional
sales milestone payments up to $1.1b in co-development, co-
commercialization pact on soluble guanylate cyclase
modulators
* Bayer to finance deal a bridge facility provided by Bank of
America, Merrill Lynch, BNP Paribas and Mizuho
* Morgan Stanley advised Merck
* Transaction expected to close in 2H
* Merck expects after-tax proceeds from the sale of MCC to be
$8b-$9b
* Merck conf. call 9am 706-634-2289 pin 42688075
* NOTE: May 2, Bayer Said to Be in Exclusive Talks for Merck
Consumer Unit {NSN N4XVM36JTSEB <go>}
Link to Statement:{NSN N55D40MEQTXN <GO>}
Link to Company News:{BAYN GR <Equity> CN <GO>}
Link to Company News:{MRK US <Equity> CN <GO>}
For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}
To contact the editor responsible for this story:
Joanna Ossinger at +1-212-617-7789 or
jossinger@bloomberg.net
Hello,
Makor securities LLP has decided to participate to the Extel Pan-European Survey this year.
Please spare 5 minutes to vote for us in the Special Situations Section.
Please vote for Makor Securities online as described below at www.extelsurveys.com<http://www.extelsurveys.com/> when logged with your credentials.
Once signed in, please click on VOTE NOW and follow the path as shown on the screen shot below
Thank You
[cid:image001.png@01CF53D0.57BCD5D0]
Makor Capital
11 Menachem Begin St., 26th FL
Ramat Gan 52681
Israel
Tel +972 3 5453 768
Fax +972 3 7162 680
Research Disclaimer
This publication has been prepared by Makor Capital Limited (“Makor Capital”) and is intended for professional or qualified investors only. Makor Securities LLP (“Makor Securities”)is distributing this material to its clients who are Eligible Counterparties or Professional Clients under FSA Rules. It may also be disseminated to persons who are Investment Professionals within the meaning of the Financial Services and Markets Act 2000 (Financial Promotion) order 2005. In the United States Makor Capital only distributes this material to major US institutional investors (as that term is defined in Rule 15 a-6 of the Securities and Exchange Act of 1934) and to SEC registered broker-dealers or banks acting in a broker –dealer capacity” If you do not fall into any of these categories you should disregard it.
This research material is a marketing communication. It is not investment research and has not been prepared in accordance with legal requirements designed to promote the independence of investment research. It is not subject to any prohibition on dealing ahead of the dissemination of investment research. It has not been produced by Makor Securities.
This material does not take into account the particular investment objectives, financial situation or needs of individual clients or other recipients. Before acting on this material, clients and other recipients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.
This material should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action.
This material is produced by research providers which Makor Securities believes to be reliable, but Makor Securities does not warrant or represent (expressly or impliedly) that it is accurate, complete, not misleading or as to its fitness for the purpose intended and it should not be relied upon as such.
Opinions expressed will be the current opinions of those producing the research as of the date appearing on this material only. We expect those producing the material in this report to update it on a timely basis but can give no undertaking that they will do so and regulatory compliance or other reasons may prevent them from doing so (or us from disseminating updated material).
Members and employees of Makor Securities LLP, employees of Makor Capital, Makor Capital Markets and any firm producing this material (including Alternative Investment Management Research SA (“AIM&R”),) may from time to time have long or short positions in securities, warrants, futures, options, derivatives or other financial instruments referred to in this material. For Makor Securities, this information is set out in our Conflicts of Interest Policy which is available on request. Policies for the production of research from research providers (including AIM&R) are available on request.
Unless otherwise stated, share prices provided within this material are as at the close of business on the day prior to the date of the material.
Neither the whole nor any part of this material may be duplicated in any form or by any means. Neither should any of this material be redistributed or disclosed to anyone without prior consent. This material is issued for general information and discussion purposes only. None of Makor Securities, Makor Capital, Makor Capital Markets nor AIM&R accepts liability whatsoever for any direct, indirect or consequential loss or damage of any kind arising out of the use of all or any of this material.
The services, securities and investments discussed in this material may not be available to, nor are suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and it should be noted that investment involves risk, including the risk of capital loss. Past performance is no guide to future performance. In relation to securities denominated in foreign currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable.
Entities
Makor Securities LLP is authorised and regulated by the Financial Services Authority (FSA registration number 556034) of Dover House, 34 Dover Street, London W1S 4NG.
Makor Capital, company number 514456466, is incorporated in Israel and is a 100% held subsidiary of Makor Holdings Pte Ltd incorporated in Singapore.
Makor Capital Markets SA, company number CH-660.2.999.011-0 is incorporated in Switzerland and is also a 100% held subsidiary of Makor Holdings Pte Ltd.
AIM&R is incorporated in Switzerland; company number CH-660.1.533.997-8
Rumours of Nokia Bid for Alcatel-Lucent Reappear {http://www.cellular-news.com/story/Business/65728.php}
Published on: 5th May 2014
The on off rumours that Nokia might launch a takeover bid for Alcatel Lucent are on again with comments by an IDC analyst that such a bid could be considered.
Nokia\'s new CEO, Rajeev Suri has already suggested that the company -- which is now mostly made up of its former NSN subsidiary -- might make some small acquisitions to fill gaps.
However, Nabila Popal, research manager at IDC MEA has suggested that Nokia could use the cash from its Microsoft deal to launch a full bid for Alcatel-Lucent.
Alcatel-Lucent is currently in the midst of a major round of job cuts to restore its profitability. Having just carried out a similar exercise at NSN, Rajeev Suri is thought to be wary of absorbing another company that needs the same treatment.
"Although the job cuts may postpone the takeover in the near future, Nokia would wait to see whether Alcatel-Lucent\'s financial performance improves as a result," Popal explained to ITP.
Rumours that NSN might make a bid for Alactel-Lucent first emerged last year, but were apparently not supposed by board talks between the two companies.
The two companies have some overlaps, but are largely complimentary in technology terms. Alcatel-Lucent is also generally thought to be stronger at winning contracts in the increasingly important Chinese market.